Selection Strategies and Practical Application of BRAF V600E-Mutated Non–Small Cell Lung Carcinoma
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: The incidence of BRAF V600E mutation in non-small cell lung carcinoma (NSCLC) is lower than 2%, which poses difficulties in finding legitimate patients for targeted therapy. We investigated the predictive factors pertaining to BRAF V600E and the effectiveness of the VE1 antibody as a screening method for patient selection. Materials and methods: The study was designed into two steps. In a first group, BRAF-mutated NSCLCs were identified from sequencing data to determine the features of BRAF V600E mutation. The results of the first group helped the collection of adenocarcinomas with a papillary or micropapillary pattern but without EGFR or ALK alterations as a second group so that the frequency of BRAF V600E mutation could be calculated. The sensitivity and specificity of the VE1 were compared with BRAF V600E status. Results: Among 39 BRAF-mutated NSCLCs in the first group, 20 (51%) were V600E. BRAF V600E mutation was more common in female patients and showed no significant correlation with smoking status. Nineteen cases were adenocarcinomas without EGFR and ALK alterations. The most common patterns of invasion were papillary and micropapillary along with central fibrosis. The sensitivity and specificity of the VE1 were 90.0% and 92.3%, respectively. In the second group, 6.7% of cases were VE1-positive, indicating that the prevalence was significantly higher than that reported in previous studies (0.3-1.8%). Conclusion: BRAF V600E-mutated NSCLCs could be enriched with the application of clinicopathologic parameters, which are not perfect. Therefore, additional VE1 immunohistochemistry may be useful as a screening method.
Abstract
Purpose: The incidence of BRAF V600E mutation in non-small cell lung carcinoma (NSCLC) is lower than 2%, which poses difficulties in finding legitimate patients for targeted therapy. We investigated the predictive factors pertaining to BRAF V600E and the effectiveness of the VE1 antibody as a screening method for patient selection. Materials and methods: The study was designed into two steps. In a first group, BRAF-mutated NSCLCs were identified from sequencing data to determine the features of BRAF V600E mutation. The results of the first group helped the collection of adenocarcinomas with a papillary or micropapillary pattern but without EGFR or ALK alterations as a second group so that the frequency of BRAF V600E mutation could be calculated. The sensitivity and specificity of the VE1 were compared with BRAF V600E status. Results: Among 39 BRAF-mutated NSCLCs in the first group, 20 (51%) were V600E. BRAF V600E mutation was more common in female patients and showed no significant correlation with smoking status. Nineteen cases were adenocarcinomas without EGFR and ALK alterations. The most common patterns of invasion were papillary and micropapillary along with central fibrosis. The sensitivity and specificity of the VE1 were 90.0% and 92.3%, respectively. In the second group, 6.7% of cases were VE1-positive, indicating that the prevalence was significantly higher than that reported in previous studies (0.3-1.8%). Conclusion: BRAF V600E-mutated NSCLCs could be enriched with the application of clinicopathologic parameters, which are not perfect. Therefore, additional VE1 immunohistochemistry may be useful as a screening method.
참고문헌 (28)
- 홍세리, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2017", Cancer Research and Treatment, 52(2), pp.335~350 (2020), 대한암학회
- Siegel RL, "Cancer statistics, 2021", CA Cancer J Clin, 71, pp.7~33 (2021)
- Khunger A, "Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer : clinical evidence and experience", Ther Adv Respir Dis, 12, pp.1753466618767611~ (2018)
- Ettinger DS, "NCCN guidelines insights: non-small cell lung cancer, version 2.2021", J Natl Compr Canc Netw, 19, pp.254~266 (2021)
- Odogwu L, "FDA approval summary : dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations", Oncologist, 23, pp.740~745 (2018)
- Ilie M, "Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients", Ann Oncol, 24, pp.742~748 (2013)
- Villaruz LC, "Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium", Cancer, 121, pp.448~456 (2015)
- Li S, "Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer : a comprehensive mutation profiling from 5125 Chinese cohorts", Br J Cancer, 110, pp.2812~2820 (2014)
- Kobayashi M, "Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer", Anticancer Res, 31, pp.4619~4623 (2011)
- Yao Z, "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS", Nature, 548, pp.234~238 (2017)
- Planchard D, "Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer : an open-label, phase 2 trial", Lancet Oncol, 18, pp.1307~1316 (2017)
- Sivakumar S, "Genomic landscape of atypical adenomatous hyperplasia reveals divergent modes to lung adenocarcinoma", Cancer Res, 77, pp.6119~6130 (2017)
- Kobayashi Y, "Ground-glass nodules of the lung in never-smokers and smokers : clinical and genetic insights", Transl Lung Cancer Res, 7, pp.487~497 (2018)
- Marchetti A, "Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations", J Clin Oncol, 29, pp.3574~3579 (2011)
- Litvak AM, "Clinical characteristics and course of 63 patients with BRAF mutant lung cancers", J Thorac Oncol, 9, pp.1669~1674 (2014)
- Tissot C, "Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations", Lung Cancer, 91, pp.23~28 (2016)
- Cardarella S, "Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer", Clin Cancer Res, 19, pp.4532~4540 (2013)
- Gow CH, "Validation of immunohistochemistry for the detection of BRAF V600E-mutated lung adenocarcinomas", Cancers(Basel), 11, pp.866~ (2019)
- Paik PK, "Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations", J Clin Oncol, 29, pp.2046~2051 (2011)
- Dagogo-Jack I, "Impact of BRAF mutation class on disease characteristics and clinical outcomes in BRAF-mutant lung cancer", Clin Cancer Res, 25, pp.158~165 (2019)
- Dearden S, "Mutation incidence and coincidence in non small-cell lung cancer : meta-analyses by ethnicity and histology(mutMap)", Ann Oncol, 24, pp.2371~2376 (2013)
- Yousem SA, "The histopathology of BRAF-V600E-mutated lung adenocarcinoma", Am J Surg Pathol, 32, pp.1317~1321 (2008)
- Kim HC, "Frequency and clinical features of BRAF mutations among patients with stage III", IV lung adenocarcinoma without EGFR, Onco Targets Ther, pp.2019, 12[DOI]
- Suzuki K, "Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung", Ann Tho-rac Surg, 69, pp.893~897 (2000)
- Harle A, "Detection of BRAF mutations using a fully automated platform and comparison with high resolution melting, real-time allele specific amplification, immunohistochemistry and next generation sequencing assays, for pati-ents with metastatic melanoma", PLoS One, 11, pp.e0153576~ (2016)
- Sasaki H, "Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma", Lung Cancer, 82, pp.51~54 (2013)
- Hofman V, "Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry : a single laboratory experience(LPCE, Nice, France)", Lung Cancer, 145, pp.58~62 (2020)
- Jones RT, "Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of cilia", Mod Pathol, 28, pp.596~606 (2015)